Global Prosthetic Heart ValvesMarket
In general, bioprostheticvalves are composed of animal tissues that are mounted on a metal or polymersupport. These valves are harvested from the cow heart sac (bovine) or porcine(pig’s) heart valves. The less invasive procedure to replace the damaged aorticvalve with bioprosthetic aortic valve is the percutaneous aortic valvereplacement (PAVR). Transcatheter mitral valve repair is a minimally invasiveprocedure for the treatment of degenerative mitral regurgitation (MR) disorder,mostly affecting the ageing population.
The global prosthetic heart valves market is estimated to garner up to US$21,968.6 million, in terms of value, by the end of 2027.
Increasingheart valve implantation procedures to bolster the global market expansion
Rising number ofheart valve implantation procedures being performed globally is expected topropel the growth of the global prosthetic heart valves market over theforecast period. For instance, in the study titled ‘Annual number of candidatesfor transcatheter aortic valve implantation per country: current estimates andfuture projections’, published in the European Heart Journal in July 2018, itwas estimated that 114,757 and 58,556 candidates get transcatheter aortic valveimplantation done in Europe and Northern America respectively, each year.
* The sample copy includes: Report Summary,Table of Contents, Segmentation, Competitive Landscape, Report Structure,Methodology.
Request a sample copy of this report:https://www.coherentmarketinsights.com/insight/request-sample/69
Mechanical heartvalves are the most commonly used prosthetic heart valves in the treatment ofpatients with a valvular heart disease. These valves are highly durable andbring out favorable outcomes on usage, as compared to tissue heart valves.However, tissue heart valves are more preferable for the treatment of geriatricpatients, as these are accepted much faster by the body. Therefore, numerouscompanies are working on the improvement of tissue heart valve (bioprostheticvalve) implantation products, in order to expand their lifespan, and thusincrease their adoption.
In contrast, increasingproduct recalls is predicted to hamper the growth of the global prostheticheart valves market in the near future. For instance, in August 2019, EdwardsLifesciences recalled its Sapien 3 Ultra replacement heart valve amid risk ofbursting of balloons during the implantation of the transcatheter aortic valve.
Key Market Takeaways
Thebiological/tissue heart valves segment held the foremost position in the globalprosthetic heart valves market in 2019, accounting for an impressive 42.0% share, in terms ofvalue. Increasing heart valve implantation procedures is expected to fuel the demandfor prosthetic heart valves over the forecast timeframe.
Moreover, the transcatheterheart valves segment in the global prosthetic heart valves market was valued atUS$ 2,572.8 million in 2019 and is expected to reach US$ 6,874.8 million overthe projected period, displaying a CAGR of 13.1%. Burgeoning prevalence ofvalvular heart disease (VHD) is poised to drive the segmental growth in theupcoming years.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/prosthetic-heart-valve-market-69
The prevalence rateof congenital heart disease has been found to be high among children,especially in the developing nations, which in turn, fosters the demand forprosthetic heart valves worldwide. According to a study, titled ‘Prevalence,profile, and pattern of congenital heart disease in Central India: A prospective,observational study’, published in May 2018, the prevalence rate of congenitalheart disease was valued at 10.13/1000 live births.
CompetitiveLandscape
The major playersoperating in the global prosthetic heart valves market include Edwards LifesciencesCorporation, Medtronic Plc, Boston Scientific Corporation, Abbott Laboratories,LivaNova PLC, CryoLife, Inc., Braile Biomedica, Colibri Heart Valve, LLC, andJenaValve Technology, Inc.
Key Developments
In September2019, Medtronic Plc launched the Evolut PRO+ TAVR System, which is anew-generation TAVR system intended for the treatment of patients withsymptomatic severe aortic stenosis, who are at a low risk of surgical mortality.Furthermroe, in February 2019, LivaNova PLC received reimbursement for itsPerceval sutureless aortic heart valve in Japan from the Ministry of Health,Labor and Welfare, for the treatment of the aortic valve disease.
Buy-Now thisresearch report: https://www.coherentmarketinsights.com/insight/buy-now/69
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
Contact Us:
mailto:sales@coherentmarketinsights.com
U.S. Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200 Seattle,WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
